SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 -- Organizational restructuring to focus resources on ...

Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the closing of its ...

Bolt Biotherapeutics, Inc. ( (BOLT) ) has released its Q3 earnings. Here is a breakdown of the information Bolt Biotherapeutics, Inc. presented ...

Detailed price information for Sonnet Biot Inc (SONN-Q) from The Globe and Mail including charting and trades.

Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.

Sonnet BioTherapeutics Holdings, Inc. disclosed in an 8-K filing with the SEC on November 6, 2024, that it has successfully completed an underwritten public offering aimed at raising $5.0 million in ...

Calidi Biotherapeutics (NYSE American: CLDI) has announced plans to sell shares of its common stock and/or pre-funded warrants in a <a target ...

BOSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage company focused on the discovery and development of next-generation therapeutics for cancer ...

Collaboration Revenue - Collaboration revenue was $1.1 million for the quarter ended September 30, 2024, compared to $2.5 ...

Company to host conference call and webcast today at 8:30 a.m. EST CARMIEL, Israel, Nov. 14, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE-American: PLX), a biopharmaceutical company ...